Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes

References

• Ekoé J-M, Zimmet P, Williams R. The Epidemiology of Diabetes Mellitus. An International Perspective. Chichester: Wiley, 2001
   Google Scholar
• Kuzuya T. Survey of diabetes mellitus by Ministry of Health and Welfare in 1997. Endocrinol Diabetol 2002;14:242-48
   Google Scholar
• Investigation report of the actual situation of diabetes mellitus. Ministry of Health, Labour and Welfare, Health Service Bureau, 2004. Available at: www.mhlw.go.jp/shingi/2004/03/s0318-15.html [Last accessed 28 April 2009]
   Google Scholar
• Matsuoka K. Genetic and environmental interaction in Japanese type 2 diabetics. Diabetes Res Clin Pract 2000;50:S17-22
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Yamazaki K, Hirao K, et al. The status of diabetes control and antidiabetic drug therapy in Japan – A cross-sectional survey of 17,000 patients with diabetes mellitus (JDDM 1). Diabetes Res Clin Pract 2006;73:198-204
   Google Scholar
• Knop FK, Holst JJ, Vilsbøll T. Replacing SUs with incretin-based therapies for type 2 diabetes mellitus: challenges and feasibility. IDrugs 2008;11:497-501
   Google Scholar
• Vilsbøll T, Krarup T, Madsbad S, et al. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia 2002;45:1111-19
   Google Scholar
• Højberg PV, Zander M, Vilsbøll T, et al. Near normalisation of blood glucose improves the potentiating effect of GLP-1 on glucose-induced insulin secretion in patients with type 2 diabetes. Diabetologia 2008;51:632-40
   Google Scholar
• Chang AM, Jakobsen G, Sturis J, et al. The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes 2003;52:1786-91
   Google Scholar
• Vilsbøll T, Zdravkovic M, Le-Thi T, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007;30:1608-10
   Google Scholar
• Vilsbøll T, Brock B, Perrild H, et al. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. Diabet Med 2008;25:152-6
   Google Scholar
• Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373:473-81
   Google Scholar
• Seino Y, Rasmussen MF, Zdravkovic M, et al. Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: a double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2008;81:161-8
   Google Scholar
• American Diabetes Association. Standards of medical care in diabetes – 2008. Diabetes Care 2008;31(Suppl. 1):S12-54
   Google Scholar
• Japan Diabetes Society. Treatment objective and index for blood glucose control. In: Japan Diabetes Society (ed.) Guidance for Diabetes Therapy 2006–2007 (article in Japanese). Japan: Bunkodo Co., Ltd, 2006
   Google Scholar
• Bock T, Pakkenberg B, Buschard K. The endocrine pancreas in non-diabetic rats after short-term and long-term treatment with the long-acting GLP-1 derivative NN2211. APMIS 2003;111:1117-24
   Google Scholar
• Sturis J, Gotfredsen CF, Rømer J, et al. GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics. Br J Pharmacol 2003;140:123-32
   Google Scholar
• Bregenholt S, Møldrup A, Blume N, et al. The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro. Biochem Biophys Res Commun 2005;330:577-84
   Google Scholar
• Rutti S, Prazak R, Ellingsgaard H, et al. Liraglutide induces human beta cell proliferation, counteracts low density lipoprotein antiproliferative effects and protects from IL-1β-induced apoptosis. Diabetes 2009;1592-P (Abstract)
   Google Scholar
• Guideline for management of postmeal glucose. International Diabetes Federation, 2007. Available at: www.idf.org/webdata/docs/Guideline_PMG_final.pdf [Last accessed 14 April 2009]
   Google Scholar
• Japan Diabetes Society. Advances in Diabetology: Proceedings from the 38th Annual Postgraduate Courses (in Japanese) Japan: Japan Diabetes Society. 2004;71-5
   Google Scholar